An open label, randomized, comparative study of Zerit (d4T) [stavudine] + Videx (ddI) [didanosine] + Crixivan [indinavir] versus Retrovir (AZT) [zidovudine] + Epivir (3TC) [lamivudine] + Crixivan in HIV-infected, antiretroviral naive subjects with CD4 cell counts of 200 - 700/mm3 and HIV RNA baseline copy number of at least 10,000 copies/mL

Trial Profile

An open label, randomized, comparative study of Zerit (d4T) [stavudine] + Videx (ddI) [didanosine] + Crixivan [indinavir] versus Retrovir (AZT) [zidovudine] + Epivir (3TC) [lamivudine] + Crixivan in HIV-infected, antiretroviral naive subjects with CD4 cell counts of 200 - 700/mm3 and HIV RNA baseline copy number of at least 10,000 copies/mL

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Dec 2006

At a glance

  • Drugs Didanosine; Indinavir; Lamivudine; Stavudine; Zidovudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top